These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27785066)

  • 1. Biomarker discovery to improve prediction of breast cancer survival: using gene expression profiling, meta-analysis, and tissue validation.
    Meng L; Xu Y; Xu C; Zhang W
    Onco Targets Ther; 2016; 9():6177-6185. PubMed ID: 27785066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Coagulation-Related Gene-Based Prognostic Model for Invasive Ductal Carcinoma.
    Li J; Du J; Wang Y; Jia H
    Front Genet; 2021; 12():722992. PubMed ID: 34621293
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation.
    Botling J; Edlund K; Lohr M; Hellwig B; Holmberg L; Lambe M; Berglund A; Ekman S; Bergqvist M; Pontén F; König A; Fernandes O; Karlsson M; Helenius G; Karlsson C; Rahnenführer J; Hengstler JG; Micke P
    Clin Cancer Res; 2013 Jan; 19(1):194-204. PubMed ID: 23032747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Carboxypeptidase B1 a Prognostic Marker for Ductal Carcinoma In Situ?
    Kothari C; Clemenceau A; Ouellette G; Ennour-Idrissi K; Michaud A; Diorio C; Durocher F
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33917306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards the early detection of ductal carcinoma (a common type of breast cancer) using biomarkers linked to the PPAR(γ) signaling pathway.
    Sultan G; Zubair S; Tayubi IA; Dahms HU; Madar IH
    Bioinformation; 2019; 15(11):799-805. PubMed ID: 31902979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-omics signature to predict the prognosis of invasive ductal carcinoma of the breast.
    Lin Z; He Y; Qiu C; Yu Q; Huang H; Yiwen Zhang ; Li W; Qiu T; Xiaoping Li
    Comput Biol Med; 2022 Dec; 151(Pt A):106291. PubMed ID: 36395590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
    Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
    Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
    Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY
    Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis.
    Mylonas I; Jeschke U; Shabani N; Kuhn C; Friese K; Gerber B
    Oncol Rep; 2005 Jan; 13(1):81-8. PubMed ID: 15583806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Landscape of Invasive Ductal Carcinoma Tumor Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature.
    Bao X; Shi R; Zhang K; Xin S; Li X; Zhao Y; Wang Y
    Front Oncol; 2019; 9():903. PubMed ID: 31620363
    [No Abstract]   [Full Text] [Related]  

  • 12. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
    Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ
    Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
    Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
    Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer.
    Yu BH; Li BZ; Zhou XY; Shi DR; Yang WT
    Diagn Pathol; 2018 May; 13(1):36. PubMed ID: 29848352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer.
    Wang L; Lyu S; Wang S; Shen H; Niu F; Liu X; Liu J; Niu Y
    Exp Mol Pathol; 2016 Feb; 100(1):177-83. PubMed ID: 26721716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
    Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis.
    Merdad A; Karim S; Schulten HJ; Dallol A; Buhmeida A; Al-Thubaity F; Gari MA; Chaudhary AG; Abuzenadah AM; Al-Qahtani MH
    Anticancer Res; 2014 Mar; 34(3):1355-66. PubMed ID: 24596383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.
    Ruszczyk M; Zirpoli G; Kumar S; Bandera EV; Bovbjerg DH; Jandorf L; Khoury T; Hwang H; Ciupak G; Pawlish K; Schedin P; Masso-Welch P; Ambrosone CB; Hong CC
    Cancer Causes Control; 2016 Feb; 27(2):183-98. PubMed ID: 26621543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.